logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shigehira Saji

department of medical oncology
H指数:47
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

甲磺酸艾瑞布林与多西他赛或紫杉醇联合曲妥珠单抗和帕妥珠单抗作为HER2阳性局部晚期或转移性乳腺癌的一线治疗的疗效和安全性：JBCRG-M06/EMERALD研究的更新亚组分析

Breast Cancer Research and Treatment
IF3
2026-07-080
PRE
Norikazu Masuda; Shigehira Saji; Yasuyuki Kojima; Masahiro Kitada; Hiroshi Tada; Tsutomu Iwasa; Kei Koizumi; Tsuguo Iwatani; Yasuaki Sagara; Takashi Kuwayama; Masafumi Shimoda; Tatsunari Sasada; Koichiro Tsugawa; Yoshihiro Kawaguchi; Akihiko Shimomura; Takuhiro Yamaguchi; Hiroki Hasegawa; Shun Osaka; Satoshi Morita; Toshinari Yamashita
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer

在JBCRG-M06/EMERALD研究中评估厄洛替尼联合双重HER2阻断在HER2阳性局部晚期或转移性乳腺癌中的生活质量评估

Breast Cancer
IF2.9
2026-06-100
PRE
Tsuguo Iwatani; Norikazu Masuda; Shigehira Saji; Takuhiro Yamaguchi; Yasuyuki Kojima; Masahiro Kitada; Hiroshi Tada; Tsutomu Iwasa; Kei Koizumi; Hideo Shigematsu; Yasuaki Sagara; Toshitaka Okuno; Yoshie Hasegawa; Eriko Tokunaga; Tadahiko Shien; Uhi Toh; Hiroki Hasegawa; Shun Osaka; Satoshi Morita; Toshinari Yamashita
Author Correction: Advancing equitable access to innovation in breast cancer

作者更正：促进乳腺癌创新成果的公平获取

npj Breast Cancer
IF7.6
2025-12-160
OAAI
Seamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werutsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study

激素受体阳性HER2阴性乳腺癌局部区域复发切除术后辅助化疗与预后的关系：一项多中心回顾性研究

ESMO Open
IF8.3
2025-11-070
OAAI
Y. Ozaki; E. Tokuda; Y. Sagara; F. Hara; S. Sasada; M. Sawaki; C. Kanbayashi; T. Yamanaka; T. Onishi; Y. Fujiki; A. Suto; Y. Takahashi; E. Tokunaga; T. Aruga; R. Nakamura; T. Fujisawa; S. Saji; H. Iwata; T. Shien
Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese National Clinical Database-Breast Cancer Registry

比较生物亚型下乳腺癌鳞状细胞癌患者与浸润性导管癌患者的生存情况：基于日本国家临床数据库-乳腺癌登记系统的匹配分析

breast
IF0
2025-08-270
OAAI
Mami Ogita; Hiraku Kumamaru; Makoto Kubo; Naoko Kinukawa; Naoki Niikura; Shigehira Saji; Masakazu Toi
Advancing equitable access to innovation in breast cancer

促进乳腺癌创新的公平获取

npj Breast Cancer
IF7.6
2025-07-100
OAAI
Seamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werustsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial

转移性乳腺癌原发肿瘤切除加全身治疗与单纯全身治疗的比较 (JCOG1017，prim-bc): 一项随机临床试验

British Journal of Cancer
IF6.8
2025-07-040
OAAI
Tadahiko Shien; Fumikata Hara; Kenjiro Aogi; Yasuhiro Yanagida; Michiko Tsuneizumi; Naohito Yamamoto; Hiroshi Matsumoto; Akihiko Suto; Kenichi Watanabe; Michiko Harao; Chizuko Kanbayashi; Mitsuya Itoh; Takayuki Kadoya; Keisei Anan; Shigeto Maeda; Keita Sasaki; Gakuto Ogawa; Shigehira Saji; Haruhiko Fukuda; Hiroji Iwata
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer

更正：来自日本的真实世界证据显示，在接受CDK4/6抑制剂联合内分泌疗法作为一线或二线治疗激素受体阳性、HER2阴性晚期或转移性乳腺癌患者的生存结局及治疗顺序方面的数据。

Breast Cancer
IF2.9
2025-06-230
OAAI
Tetsuhiro Yoshinami; Yuko Takano; Yukinori Ozaki; Yukiko Kajiwara; Mitsugu Yamamoto; Ken-ichi Watanabe; Masami Tsukabe; Fumie Fujisawa; Shigenori E. Nagai; Nobuhiro Shibata; Chiya Oshiro; Hiroko Bando; Nobuyuki Tsunoda; Kazuhiko Yamagami; Kei Koizumi; Masahiro Takada; Naoko Toriguchi; Nobuyuki Sekine; Tsutomu Kawaguchi; Shigehira Saji; Yasuaki Sagara; Satoshi Morita; Norikazu Masuda
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

来自日本的真实世界证据，关于接受CDK4/6抑制剂联合内分泌治疗作为激素受体阳性、HER2阴性晚期或转移性乳腺癌的一线或二线治疗患者的生存结局及治疗顺序。

BREAST CANCER
IF2.9
2025-05-200
OA
Yoshinami, Tetsuhiro; Takano, Yuko; Ozaki, Yukinori; Kajiwara, Yukiko; Yamamoto, Mitsugu; Watanabe, Ken-ichi; Tsukabe, Masami; Fujisawa, Fumie; Nagai, Shigenori E.; Shibata, Nobuhiro; Oshiro, Chiya; Bando, Hiroko; Tsunoda, Nobuyuki; Yamagami, Kazuhiko; Koizumi, Kei; Takada, Masahiro; Toriguchi, Naoko; Sekine, Nobuyuki; Kawaguchi, Tsutomu; Saji, Shigehira; Sagara, Yasuaki; Morita, Satoshi; Masuda, Norikazu
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status

2021年国家临床数据库—乳腺癌登记系统年度报告：按体重指数和绝经状态分类的特征

BREAST CANCER
IF2.9
2025-04-210
OA
Konishi, Takaaki; Kumamaru, Hiraku; Niikura, Naoki; Sagara, Yasuaki; Miyashita, Minoru; Iwamoto, Takayuki; Sanuki, Naoko; Tanakura, Kenta; Nagahashi, Masayuki; Yoshida, Masayuki; Kawashima, Masahiro; Kinoshita, Takayuki; Sasada, Shinsuke; Kinukawa, Naoko; Saji, Shigehira; Ishida, Takanori; Taira, Naruto
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

TROPION-Breast05：一项关于Dato-DXd联合或不联合durvalumab与化疗联合pembrolizumab治疗PD-L1高表达局部复发不可手术或转移性三阴性乳腺癌的随机III期研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-04-170
OA
Peter Schmid; Mafalda Oliveira; Joyce O’Shaughnessy; Massimo Cristofanilli; Stephanie L. Graff; Seock-Ah Im; Sherene Loi; Shigehira Saji; Shusen Wang; David W. Cescon; Tina Hovey; Agata Nawrot; Karson Tse; Petra Vukovic; Giuseppe Curigliano
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression
BREAST CANCER
IF2.9
2025-02-060
OAAI
Nagahashi, Masayuki; Kumamaru, Hiraku; Kinukawa, Naoko; Iwamoto, Takayuki; Kawashima, Masahiro; Kinoshita, Takayuki; Konishi, Takaaki; Sagara, Yasuaki; Sasada, Shinsuke; Saji, Shigehira; Sanuki, Naoko; Tanakura, Kenta; Niikura, Naoki; Miyashita, Minoru; Yoshida, Masayuki; Ishida, Takanori; Taira, Naruto
Merging of the Fukushima Health Management Survey With the National and Local Cancer Registry to Refine the Detection of Thyroid Cancer Cases After the 2011 Fukushima Daiichi Nuclear Power Plant Accident

将福岛健康管理调查与国家和地方癌症登记数据合并，以优化2011年福岛第一核电站事故后甲状腺癌病例的检测

CANCER MEDICINE
IF3.1
2025-02-060
OAAI
Kimura-Tsuchiya, Reiko; Nagao, Masanori; Saji, Shigehira; Hayashi, Fumikazu; Ohira, Tetsuya; Shimura, Hiroki; Furuya, Fumihiko; Suzuki, Satoru; Suzuki, Satoshi; Ishikawa, Tetsuo; Yokoya, Susumu; Ohto, Hitoshi; Yasumura, Seiji
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
CLINICAL CANCER RESEARCH
IF10.2
2024-07-260
OAAI
Dent, Rebecca A.; Kim, Sung-Bae; Oliveira, Mafalda; Barrios, Carlos; O'Shaughnessy, Joyce; Isakoff, Steven J.; Saji, Shigehira; Freitas-Junior, Ruffo; Philco, Manuel; Bondarenko, Igor; Lian, Qinshu; Bradley, Denise; Hinton, Heather; Wongchenko, Matthew J.; Reilly, Sarah-Jayne; Turner, Nicholas
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)
BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-06-260
PRE
Iwamoto, Takayuki; Niikura, Naoki; Watanabe, Kenichi; Takeshita, Takashi; Kikawa, Yuichiro; Kobayashi, Kokoro; Iwakuma, Nobutaka; Okamura, Takuho; Kobayashi, Takayuki; Katagiri, Yuriko; Kitada, Masahiro; Tomioka, Nobumoto; Miyoshi, Yasuo; Shigematsu, Hideo; Miyashita, Minoru; Ishiguro, Hiroshi; Masuda, Norikazu; Saji, Shigehira

研究方向

暂未获取到该数据
N
Norikazu Masuda
H 指数:64论文数:698被引数:2.9万
M
Masakazu Toi
H 指数:2论文数:8被引数:405
H
Hiroji Iwata
H 指数:89论文数:844被引数:5.6万
Y
Yutaka Yamamoto
H 指数:45论文数:328被引数:5,784
S
Shinji Ohno
H 指数:62论文数:565被引数:2.3万
N
Naoki Niikura
H 指数:34论文数:264被引数:9,093
Y
Yasuaki Sagara
H 指数:32论文数:234被引数:6,817
N
Nobuaki Sato
H 指数:38论文数:233被引数:6,096
T
Tatsuya Toyama
H 指数:51论文数:319被引数:7,452
S
Satoshi Morita
H 指数:85论文数:1,269被引数:4.0万